Changes of serum miR-34a and miR-146a before and after PCI and their short-term prognostic values in ACS patients
Objective To investigate the changes in serum miR-34a and miR-146a levels in patients with acute coronary syndrome(ACS)and the short-term prognostic value of miR-34a and miR-146a levels.Methods 86 ACS patients undergoing percutaneous coronary intervention(PCI)were selected from February 2018 to June 2020.All subjects used Judkins method for coronary angiography,and divided into groups according to the results of the coronary angiography:single-vessel disease group(23 cases),double-vessel disease group(36 cases)and three-vessel disease group(27 cases);simultaneous coronary angiography results for Gensini score,＜50 points were mild disease group(46 cases),50～90 points were moderate disease group(30 cases),＞90 points were severe disease group(10 cases).Real-time fluorescence quantitative PCR was used to detect the expression levels of miR-34a and miR-146a in ACS patients before PCI and one month after PCI.And follow up the occurrence of major adverse cardiovascular events(MACE)in ACS patients within 1 year after surgery.According to the occurrence of MACE events,the patients were divided into two groups:MACE group and non-MACE group.The expression levels of serum miR-34a and miR-146a were compared between the two groups.Results The serum miR-34a and miR-146a levels of ACS patients before PCI were significantly higher than that after PCI(P＜0.001);the expression levels of serum miR-34a and miR-146a in the moderate disease group of ACS patients were higher than those in the mild disease group(P＜0.001);while the expression levels of serum miR-34a and miR-146a in the severe disease group were significantly higher than that of the moderate disease group and the mild disease group(P＜0.001);the expression levels of serum miR-34a and miR-146a in the double-vessel disease group were higher than those in the single-vessel disease group(P＜0.05);the expression levels of serum miR-34a and miR-146a in the three-vessel disease group were significantly higher than those in the double-vessel and single-vessel groups(P＜0.05);the expression levels of serum miR-34a and miR-146a in the MACE group were significantly higher than that of patients in the non-MACE group(P＜0.001).Conclusion PCI can significantly reduce the serum miR-34a and miR-146a expression levels in ACS patients.The expression levels of serum miR-34a and miR-146a increase with the severity of coronary artery disease.Therefore,serum miR-34a and miR-146a can be used to predict the degree of coronary artery disease.At the same time,monitoring the serum miR-34a and miR-146a expression levels after PCI in ACS patients is also of great significance and can prevent the occurrence of MACE events.
万方数据
维普
